{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2FRefractory+Large+B-cell+Lymphoma+%28LBCL%29", "query": { "condition": "Relapsed/Refractory Large B-cell Lymphoma (LBCL)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 13, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2FRefractory+Large+B-cell+Lymphoma+%28LBCL%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-22T12:27:20.868Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04855253", "title": "Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "DLBCL", "Diffuse Large B Cell Lymphoma", "High-grade B-cell Lymphoma", "DLBCL Arising From Follicular Lymphoma" ], "interventions": [ { "name": "E7777", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Tisagenlecleucel", "type": "DRUG" }, { "name": "Axicabtagene Ciloleucel", "type": "DRUG" }, { "name": "Lisocabtagene Maraleucel Intravenous Suspension", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2021-06-09", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-01-15", "last_synced_at": "2026-07-22T12:27:20.868Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04855253" }, { "nct_id": "NCT05664217", "title": "NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Non-Hodgkin Lymphoma", "Relapsed/Refractory Diffuse Large B-cell Lymphoma" ], "interventions": [ { "name": "NKTR-255 at 1.5 µg/kg", "type": "DRUG" }, { "name": "NKTR-255 at 3.0 μg/kg", "type": "DRUG" }, { "name": "NKTR-255 at 3.0/6.0 μg/kg", "type": "DRUG" }, { "name": "Placebo Comparator", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Nektar Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2022-12-23", "completion_date": "2024-08-16", "has_results": false, "last_update_posted_date": "2025-02-13", "last_synced_at": "2026-07-22T12:27:20.868Z", "location_count": 22, "location_summary": "La Jolla, California • Jacksonville, Florida • Atlanta, Georgia + 17 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT05664217" }, { "nct_id": "NCT06542250", "title": "A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "B-cell Malignancies" ], "interventions": [ { "name": "AZD5492", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 174, "start_date": "2024-09-18", "completion_date": "2029-12-18", "has_results": false, "last_update_posted_date": "2026-07-21", "last_synced_at": "2026-07-22T12:27:20.868Z", "location_count": 10, "location_summary": "La Jolla, California • Boston, Massachusetts • Rochester, Minnesota + 6 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06542250" }, { "nct_id": "NCT06526793", "title": "Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "B-cell Non-Hodgkin Lymphoma", "Follicular Lymphoma (FL)", "Large B-Cell Lymphoma (LBCL)" ], "interventions": [ { "name": "Surovatamig", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 270, "start_date": "2024-11-27", "completion_date": "2032-10-21", "has_results": false, "last_update_posted_date": "2026-06-25", "last_synced_at": "2026-07-22T12:27:20.868Z", "location_count": 22, "location_summary": "Phoenix, Arizona • Duarte, California • Jacksonville, Florida + 19 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06526793" }, { "nct_id": "NCT06104592", "title": "Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Large B-cell Lymphoma", "Relapsed Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Comprehensive Ablative Bridging Irradiation (CABI)", "type": "RADIATION" }, { "name": "Chimeric Antigen Receptor T-Cell Therapy", "type": "BIOLOGICAL" } ], "intervention_types": [ "RADIATION", "BIOLOGICAL" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2023-11-08", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-03-31", "last_synced_at": "2026-07-22T12:27:20.868Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06104592" }, { "nct_id": "NCT03939026", "title": "Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed/Refractory Large B Cell Lymphoma", "Relapsed/Refractory Follicular Lymphoma" ], "interventions": [ { "name": "ALLO-501", "type": "GENETIC" }, { "name": "ALLO-647", "type": "BIOLOGICAL" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "GENETIC", "BIOLOGICAL", "DRUG" ], "sponsor": "Allogene Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2019-05-01", "completion_date": "2025-01-28", "has_results": false, "last_update_posted_date": "2026-03-02", "last_synced_at": "2026-07-22T12:27:20.868Z", "location_count": 7, "location_summary": "Gilbert, Arizona • Stanford, California • Denver, Colorado + 4 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Stanford", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT03939026" }, { "nct_id": "NCT05359211", "title": "NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "Recurrent Grade 3b Follicular Lymphoma", "Recurrent Primary Mediastinal Large B-Cell Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "Refractory Grade 3b Follicular Lymphoma", "Refractory Primary Mediastinal Large B-Cell Lymphoma", "Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Lisocabtagene Maraleucel", "type": "BIOLOGICAL" }, { "name": "Polymer-conjugated IL-15 Receptor Agonist NKTR-255", "type": "DRUG" }, { "name": "X-Ray Imaging", "type": "PROCEDURE" }, { "name": "Echocardiography", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Lumbar Puncture", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2022-12-08", "completion_date": "2026-09-04", "has_results": false, "last_update_posted_date": "2026-03-20", "last_synced_at": "2026-07-22T12:27:20.868Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT05359211" }, { "nct_id": "NCT05714345", "title": "Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Relapsed/Refractory Large B Cell Lymphoma" ], "interventions": [ { "name": "ALLO-647", "type": "BIOLOGICAL" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "ALLO-501A", "type": "GENETIC" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "GENETIC" ], "sponsor": "Allogene Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2023-11-01", "completion_date": "2024-10-28", "has_results": true, "last_update_posted_date": "2026-03-02", "last_synced_at": "2026-07-22T12:27:20.868Z", "location_count": 1, "location_summary": "Louisville, Kentucky", "locations": [ { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT05714345" }, { "nct_id": "NCT06256484", "title": "A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed/Refractory B-cell Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "ATA3219", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Atara Biotherapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 1, "start_date": "2024-09-06", "completion_date": "2025-03-30", "has_results": false, "last_update_posted_date": "2026-03-11", "last_synced_at": "2026-07-22T12:27:20.868Z", "location_count": 4, "location_summary": "Orlando, Florida • Louisville, Kentucky • Philadelphia, Pennsylvania + 1 more", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06256484" }, { "nct_id": "NCT06905509", "title": "Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements", "Recurrent High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements", "Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified", "Recurrent Nodal Marginal Zone Lymphoma", "Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "Refractory High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements", "Refractory High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements", "Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified", "Refractory Nodal Marginal Zone Lymphoma", "Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Autologous Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Epcoritamab", "type": "BIOLOGICAL" }, { "name": "Etoposide Phosphate", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "University of California, Davis", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2025-07-31", "completion_date": "2030-08-01", "has_results": false, "last_update_posted_date": "2026-06-30", "last_synced_at": "2026-07-22T12:27:20.868Z", "location_count": 1, "location_summary": "Sacramento, California", "locations": [ { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06905509" } ] }